Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02532517 · ClinicalTrials.gov registry record · NA
Study to Evaluate the Safety and Effectiveness of the CODMAN ENTERPRISE® Vascular Reconstruction Device
A NA study, sponsored by Cerenovus, Part of DePuy Synthes Products.
- Terminated
- Registry status
- NA
- Development phase
- 45
- Enrollment target
NCT02532517 is a NA study that was terminated before completion, run by Cerenovus, Part of DePuy Synthes Products. The registered enrollment target is 45 participants.
The verdict
NCT02532517, a NA study, was terminated before completion, sponsored by Cerenovus, Part of DePuy Synthes Products.
- TERMINATED
- Registry status
- NA
- Development phase
- 45 participants
- Enrollment target
Study Summary
The purpose of this study is to demonstrate effectiveness and safety of the CODMAN ENTERPRISE® Vascular Reconstruction Device and Delivery System.
Interventions
- DEVICE CODMAN ENTERPRISE® Vascular Reconstruction Device and Delivery System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2015-09-01 |
| Est. Completion | 2019-09-21 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02532517
The ClinicalTrials.gov registry entry for NCT02532517 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cerenovus, Part of DePuy Synthes Products, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CODMAN ENTERPRISE® Vascular Reconstruction Device and Delivery System is the first listed.
NCT02532517 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02532517 about?
NCT02532517 is a clinical study titled "Study to Evaluate the Safety and Effectiveness of the CODMAN ENTERPRISE® Vascular Reconstruction Device". The purpose of this study is to demonstrate effectiveness and safety of the CODMAN ENTERPRISE® Vascular Reconstruction Device and Delivery System.
What is the current status of trial NCT02532517?
This trial is currently terminated. It is a NA study. The enrollment target is 45 participants. The study started on 2015-09-01. Estimated completion is 2019-09-21.
What interventions are being tested in trial NCT02532517?
The interventions under investigation include: CODMAN ENTERPRISE® Vascular Reconstruction Device and Delivery System (DEVICE).
Who is sponsoring clinical trial NCT02532517?
This trial is sponsored by Cerenovus, Part of DePuy Synthes Products, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.